Top Page
Vital KSK Holdings, Inc.
(3151)
Vital KSK Holdings, Inc. (3151) vs. iShares MSCI Japan ETF (EWJ)
Vital KSK Holdings, Inc. Business Overview & Revenue Model
Vital KSK Holdings, Inc. Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 599.25B | 600.37B | 587.48B | 579.77B | 577.25B | 537.06B | Gross Profit |
| 49.09B | 49.22B | 48.30B | 44.96B | 43.98B | 38.22B | EBIT |
| 5.31B | 5.71B | 5.56B | 2.47B | 2.94B | -2.26B | EBITDA |
| 11.06B | 14.56B | 12.16B | 5.82B | 6.07B | 939.00M | Net Income Common Stockholders |
| 7.25B | 7.31B | 5.84B | 4.83B | 4.77B | 1.17B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 31.50B | 23.10B | 34.71B | 19.03B | 26.97B | 29.78B | Total Assets |
| 344.17B | 299.43B | 317.26B | 297.32B | 313.03B | 311.40B | Total Debt |
| 6.96B | 8.59B | 9.11B | 10.25B | 11.85B | 16.80B | Net Debt |
| -24.54B | -14.51B | -25.60B | -8.78B | -15.12B | -12.99B | Total Liabilities |
| 234.09B | 192.12B | 211.32B | 197.15B | 212.99B | 207.49B | Stockholders Equity |
| 108.71B | 105.91B | 104.66B | 98.98B | 98.96B | 102.94B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | -10.59B | 18.47B | -9.60B | 3.35B | -5.23B | Operating Cash Flow |
| 0.00 | -8.02B | 23.57B | -3.00B | 7.49B | -1.39B | Investing Cash Flow |
| 0.00 | 3.52B | -1.82B | -1.04B | -2.01B | 549.00M | Financing Cash Flow |
| 0.00 | -6.54B | -5.77B | -4.08B | -8.49B | -2.52B |
Vital KSK Holdings, Inc. Technical Analysis
Vital KSK Holdings, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥6.79B | 11.01 | 2.29% | 3.06% | -6.60% | ||
72 Outperform | ¥12.86B | 9.49 | 3.79% | 3.95% | -11.14% | ||
70 Outperform | ¥37.78B | 18.68 | 3.95% | 11.04% | 20.33% | ||
68 Neutral | ¥54.62B | 8.15 | 3.95% | 2.19% | 30.44% | ||
63 Neutral | $53.34B | 55.63 | 1.87% | 2.12% | 0.10% | -41.21% | |
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% | |
53 Neutral | ¥68.56B | ― | 3.61% | -22.86% | -186.99% |
Vital KSK Holdings, Inc. Corporate Events
Vital KSK Holdings, Inc. has announced a partial revision to its performance-linked restricted stock compensation plan for its directors, aiming to better align director incentives with shareholder interests and corporate performance. The changes include a new method for calculating performance payment ratios based on return on equity, which is intended to more accurately reflect the company’s business plans and performance levels, thereby enhancing the motivation of directors to contribute to long-term corporate value growth.
Vital KSK Holdings, Inc. announced significant organizational and personnel changes, including the merging of departments and the appointment of new directors and executive officers. These changes aim to streamline operations and enhance focus on sustainability and new business development, potentially impacting the company’s strategic direction and stakeholder engagement.
Vital KSK Holdings, Inc. has announced proposed amendments to its Articles of Incorporation, aiming to expand and diversify its business operations beyond pharmaceutical wholesale. This strategic move is intended to bolster the company’s earning power by including health-related services and other emerging business opportunities, reflecting a significant shift in its operational focus.
Vital KSK Holdings, Inc. reported a 2.2% increase in net sales for the fiscal year ending March 31, 2025, with a notable 25.1% rise in profit attributable to owners of the parent. The company also announced an increase in cash dividends per share, reflecting a positive outlook despite a decrease in comprehensive income. The financial results indicate a stable growth trajectory, with a forecasted increase in net sales and dividends for the next fiscal year, suggesting confidence in future performance.
Vital KSK Holdings, Inc. announced its plan to dispose of treasury stock as part of a performance-linked restricted stock compensation plan approved in 2023. This move, involving an estimated 128,400,000 yen, aims to incentivize directors, executive officers, and eligible employees, potentially impacting the company’s financial structure and stakeholder interests.
Vital KSK Holdings, Inc. has announced a dividend of 24.00 yen per share for the fiscal year ended March 31, 2025, reflecting its commitment to returning profits to shareholders. The company aims for a dividend on equity ratio of 2% or more and a total return ratio policy of 50% or more, indicating a focus on shareholder value.
Vital KSK Holdings, Inc. announced a resolution to amend its Performance-Linked Restricted Stock Compensation Plan, which will be proposed at the upcoming Annual General Meeting of Shareholders. This amendment reflects the company’s ongoing efforts to align executive compensation with performance, potentially impacting shareholder value and corporate governance practices.
Vital KSK Holdings, Inc. has announced a resolution to propose amendments to its Articles of Incorporation at the upcoming Annual General Meeting of Shareholders. This move could potentially impact the company’s governance structure and align its operations with strategic goals, affecting stakeholders and market positioning.
Vital KSK Holdings, Inc. has announced a series of organizational changes, including updates to its representative directors, directors, and executive officers. These changes will be finalized at the upcoming Annual General Meeting of Shareholders and are expected to impact the company’s governance structure and operational leadership.
Vital KSK Holdings, Inc. has announced its Medium-Term Management Plan 2027, titled ‘Move on to the Next Stage,’ which outlines the company’s strategic initiatives for the next three years starting from FY2025. This plan is expected to guide the company through its next phase of growth, potentially impacting its operational strategies and market positioning.
Vital KSK Holdings, Inc. announced that its subsidiary, VITAL-NET, Inc., has entered into an exclusive license agreement with Shield Therapeutics plc for the development and commercialization of ACCRUFeR®, an iron deficiency treatment, in Japan. This strategic move aims to expand Vital KSK’s pharmaceutical offerings in Japan, with plans to build a comprehensive distribution and sales network. The agreement involves upfront and milestone payments, as well as royalties, and is expected to enhance the company’s market position and product value chain.